Research also suggests benefits in reducing liver fat content in patients with non-alcoholic fatty liver disease/metabolic dysfunction-associated steatohepatitis (MASH), though these are not currently approved indications and represent areas of ongoing research
BOOSTING ADHERENCE TO REDUCE GLP-1 WASTAGE We help members face and overcome the challenges that come with adhering to GLP-1 therapy, allowing them to maximize its benefits and reduce the financial waste of early discontinuation
[26] [27] Keeping a simple food and symptom diary during the early weeks of treatment can help identify personal trigger foods and provide useful information to share with the healthcare team
There are also emerging geographic and demographic disparities: studies have found lower GLP-1 fill rates among patients with obesity (37% fill rate) versus those with diabetes (4765% fill) ( [30] ), and lower fill rates for Hispanic and Black patients, reflecting both socioeconomic and coverage gaps ( [31] )
doi: 10.1007/s11102-022-01297-x 146 TaghaviSMFatemiSSRokniH
Short Takes Taken from C-SPAN's gavel-to-gavel coverage and condensed down to the key moments